Advances in bladder cancer biology and therapy
The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …
generation sequencing has identified the genes most mutated in bladder cancer. This …
Tumour-intrinsic resistance to immune checkpoint blockade
Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and
others have found that a subset of patients experiences paradoxical rapid cancer …
others have found that a subset of patients experiences paradoxical rapid cancer …
Inflammation and cancer: triggers, mechanisms, and consequences
FR Greten, SI Grivennikov - Immunity, 2019 - cell.com
Inflammation predisposes to the development of cancer and promotes all stages of
tumorigenesis. Cancer cells, as well as surrounding stromal and inflammatory cells, engage …
tumorigenesis. Cancer cells, as well as surrounding stromal and inflammatory cells, engage …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
SV Lindskrog, F Prip, P Lamy, A Taber… - Nature …, 2021 - nature.com
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …
Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
[HTML][HTML] Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
D Hammerl, JWM Martens, M Timmermans… - Nature …, 2021 - nature.com
Only a subgroup of triple-negative breast cancer (TNBC) responds to immune checkpoint
inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for …
inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for …
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single …
A Necchi, A Anichini, D Raggi, A Briganti… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before
radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard …
radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard …